Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 1
Submit an article Journal homepage
2,613
Views
4
CrossRef citations to date
0
Altmetric
Immunotherapy – Commentary

Future prospects for cancer immunotherapy - Strategies for ineffective cancers

Satoshi Wadaa Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan;b Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan;c Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6528-5914View further author information
ORCID Icon,
Shinichi Kobayashib Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, JapanView further author information
&
Takuya Tsunodac Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, JapanView further author information
Article: 2031699 | Received 29 Dec 2021, Accepted 18 Jan 2022, Published online: 25 Jan 2022

References

  • Davila ML, Brentjens RJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016;14:802–3.
  • Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen Y-B, Palmer E, Albertson T, Ferry JA, Arrillaga-Romany IC, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377(8):783–84. doi:10.1056/NEJMc1704610.
  • Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. doi:10.1056/NEJMoa1709866.
  • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
  • Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111. doi:10.1038/nri.2016.107.
  • Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(31):51–72. doi:10.1146/annurev-immunol-032712-100008.
  • Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. doi:10.1038/nm1523.
  • Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–76. doi:10.1038/nature14001.
  • Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90. doi:10.1126/science.aad1253.
  • Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–96. doi:10.1038/nature14426.
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
  • Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature. 2011;479(7374):542–46. doi:10.1038/nature10540.
  • Girard JP, Moussion C, Förster R. HEVs,lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12(11):762–73. doi:10.1038/nri3298.
  • Onder L, Danuser R, Scandella E, Firner S, Chai Q, Hehlgans T, Stein JV, Ludewig B. Endothelial cell-specific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J Exp Med. 2013;210(3):465–73. doi:10.1084/jem.20121462.
  • Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2010;9(385): ii: eaak9679. doi:10.1126/scitranslmed.aak9679.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.